458 related articles for article (PubMed ID: 28735814)
1. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.
Collins DM; Gately K; Hughes C; Edwards C; Davies A; Madden SF; O'Byrne KJ; O'Donovan N; Crown J
Cell Immunol; 2017 Sep; 319():35-42. PubMed ID: 28735814
[TBL] [Abstract][Full Text] [Related]
2. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
[TBL] [Abstract][Full Text] [Related]
3. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Okita R; Shimizu K; Nojima Y; Yukawa T; Maeda A; Saisho S; Nakata M
Oncol Rep; 2015 Dec; 34(6):2864-70. PubMed ID: 26503698
[TBL] [Abstract][Full Text] [Related]
5. A gene expression profile indicative of early stage HER2 targeted therapy response.
O'Neill F; Madden SF; Clynes M; Crown J; Doolan P; Aherne ST; O'Connor R
Mol Cancer; 2013 Jul; 12():69. PubMed ID: 23816254
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.
Scaltriti M; Verma C; Guzman M; Jimenez J; Parra JL; Pedersen K; Smith DJ; Landolfi S; Ramon y Cajal S; Arribas J; Baselga J
Oncogene; 2009 Feb; 28(6):803-14. PubMed ID: 19060928
[TBL] [Abstract][Full Text] [Related]
7. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
[TBL] [Abstract][Full Text] [Related]
8. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.
Boero S; Morabito A; Banelli B; Cardinali B; Dozin B; Lunardi G; Piccioli P; Lastraioli S; Carosio R; Salvi S; Levaggi A; Poggio F; D'Alonzo A; Romani M; Del Mastro L; Poggi A; Pistillo MP
J Transl Med; 2015 Oct; 13():324. PubMed ID: 26450443
[TBL] [Abstract][Full Text] [Related]
9. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Sánchez-Martín M; Pandiella A
Int J Cancer; 2012 Jul; 131(1):244-52. PubMed ID: 21826647
[TBL] [Abstract][Full Text] [Related]
10. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
11. Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Gaynor N; Blanco A; Madden SF; Moran B; Fletcher JM; Kaukonen D; Ramírez JS; Eustace AJ; McDermott MSJ; Canonici A; Toomey S; Teiserskiene A; Hennessy BT; O'Donovan N; Crown J; Collins DM
Br J Cancer; 2023 Oct; 129(6):1022-1031. PubMed ID: 37507543
[TBL] [Abstract][Full Text] [Related]
12. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
Collins DM; O'Donovan N; McGowan PM; O'Sullivan F; Duffy MJ; Crown J
Ann Oncol; 2012 Jul; 23(7):1788-95. PubMed ID: 22056974
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Conlon NT; Kooijman JJ; van Gerwen SJC; Mulder WR; Zaman GJR; Diala I; Eli LD; Lalani AS; Crown J; Collins DM
Br J Cancer; 2021 Mar; 124(7):1249-1259. PubMed ID: 33473169
[TBL] [Abstract][Full Text] [Related]
15. Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment.
Di Luca A; Henry M; Meleady P; O'Connor R
Daru; 2015 Aug; 23(1):40. PubMed ID: 26238995
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity.
Shiraishi K; Mimura K; Izawa S; Inoue A; Shiba S; Maruyama T; Watanabe M; Kawaguchi Y; Inoue M; Fujii H; Kono K
Gastric Cancer; 2013 Oct; 16(4):571-80. PubMed ID: 23187882
[TBL] [Abstract][Full Text] [Related]
17. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
Watson SS; Dane M; Chin K; Tatarova Z; Liu M; Liby T; Thompson W; Smith R; Nederlof M; Bucher E; Kilburn D; Whitman M; Sudar D; Mills GB; Heiser LM; Jonas O; Gray JW; Korkola JE
Cell Syst; 2018 Mar; 6(3):329-342.e6. PubMed ID: 29550255
[TBL] [Abstract][Full Text] [Related]
18. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
Ríos-Luci C; Díaz-Rodríguez E; Gandullo-Sánchez L; Díaz-Gil L; Ocaña A; Pandiella A
Cancer Lett; 2020 Feb; 470():161-169. PubMed ID: 31765734
[TBL] [Abstract][Full Text] [Related]
19. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
20. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
